Atara biotherapeutics presents new preclinical data on ata3271, a next-generation allogeneic mesothelin-targeted car t to treat solid tumors, at the 35th society for immunotherapy of cancer annual meeting (sitc 2020)

South san francisco, calif.--(business wire)--atara biotherapeutics, inc. (nasdaq: atra), a pioneer in t-cell immunotherapy, leveraging its novel allogeneic ebv t-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today announced the presentation of the first preclinical evaluation of ata3271, a next-generation, off-the-shelf, allogeneic ebv car t-cell therapy targeting mesothelin designed for
ATRA Ratings Summary
ATRA Quant Ranking